Pomerantz LLP is investigating claims on behalf of investors of Bellicum Pharmaceuticals, Inc. ("Bellicum" or the "Company") (NASDAQ: BLCM). Such investors are advised to contact Robert S. Willoughby at email@example.com or 888-476-6529, ext. 9980.
The investigation concerns whether Bellicum and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
On January 30, 2018, post-market, Bellicum issued a press release announcing "that the Company has received notice from the U.S. Food and Drug Administration (FDA) that U.S. studies of BPX-501", Bellicum's lead product candidate, "have been placed on a clinical hold following three cases of encephalopathy deemed as possibly related to BPX-501." On this news, Bellicum's share price has fallen sharply during intraday trading on January 31, 2018.